

Robert E Reiter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6205812/publications.pdf>

Version: 2024-02-01

172
papers

12,044
citations

30070

54
h-index

30087

103
g-index

174
all docs

174
docs citations

174
times ranked

12699
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
2	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	28.9	459
3	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	30.5	434
4	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	5.0	372
5	Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology. European Urology, 2015, 67, 569-576.	1.9	362
6	Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine, 1997, 3, 402-408.	30.7	356
7	Prostate cancer detection with magnetic resonanceâ€“ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer, 2016, 122, 884-892.	4.1	346
8	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	10.7	338
9	Value of Targeted Prostate Biopsy Using Magnetic Resonanceâ€“Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. European Urology, 2014, 65, 809-815.	1.9	337
10	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
11	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	288
12	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine, 2010, 16, 1414-1420.	30.7	280
13	LOW P27 EXPRESSION PREDICTS POOR DISEASE-FREE SURVIVAL IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 1998, 159, 941-945.	0.4	278
14	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
15	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896.	7.4	252
16	Quality of life after surgery, external beam irradiation, or brachytherapy for earlyâ€“stage prostate cancer. Cancer, 2007, 109, 2239-2247.	4.1	236
17	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664.	0.4	233
18	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	21.4	198

#	ARTICLE	IF	CITATIONS
19	Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases. <i>Clinical Cancer Research</i> , 2005, 11, 2591-2596.	7.0	195
20	Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2019, 75, 712-720.	1.9	187
21	Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging. <i>Cancer Research</i> , 2014, 74, 4638-4652.	0.9	179
22	Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. <i>Journal of Urology</i> , 2017, 197, 320-326.	0.4	173
23	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	1.9	140
24	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	7.1	138
25	Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. <i>Prostate</i> , 2010, 70, 491-501.	2.3	130
26	Use of MR Imaging to Determine Preservation of the Neurovascular Bundles at Robotic-assisted Laparoscopic Prostatectomy. <i>Radiology</i> , 2012, 262, 874-883.	7.3	124
27	Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology. <i>Journal of Urology</i> , 2014, 192, 1367-1373.	0.4	121
28	First-in-Human Imaging with ⁸⁹ Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	5.0	116
29	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 434-441.	5.0	113
30	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncolmmunology</i> , 2018, 7, e1380764.	4.6	111
31	Prostate Stem Cell Antigen Expression is Associated With Gleason Score, Seminal Vesicle Invasion and Capsular Invasion in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 1117-1121.	0.4	110
32	Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. <i>Molecular Cancer Research</i> , 2002, 1, 113-21.	3.4	107
33	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	1.9	104
34	Androgen Receptor and Invasion in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 1128-1135.	0.9	102
35	The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 473-479.	1.6	100
36	Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. <i>American Journal of Roentgenology</i> , 2015, 205, W87-W92.	2.2	98

#	ARTICLE	IF	CITATIONS
37	Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. , 2000, 27, 95-103.		97
38	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. Journal of Nuclear Medicine, 2020, 61, 1153-1160.	5.0	94
39	LEF1 in Androgen-Independent Prostate Cancer: Regulation of Androgen Receptor Expression, Prostate Cancer Growth, and Invasion. Cancer Research, 2009, 69, 3332-3338.	0.9	89
40	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	7.1	87
41	Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nature Protocols, 2011, 6, 656-667.	12.0	86
42	Clinical Outcomes for Patients with Gleason Score 9â€“10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology, 2017, 71, 766-773.	1.9	83
43	Antiâ€“Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent Mechanism. Cancer Research, 2005, 65, 9495-9500.	0.9	82
44	Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer. Pancreas, 2005, 31, 119-125.	1.1	81
45	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721.	5.0	81
46	The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 268-276.	1.6	76
47	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	5.0	74
48	Automatic Prostate Zonal Segmentation Using Fully Convolutional Network With Feature Pyramid Attention. IEEE Access, 2019, 7, 163626-163632.	4.2	71
49	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	10.7	68
50	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	3.9	66
51	Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigenâ€“Expressing Tumors. Clinical Cancer Research, 2008, 14, 7488-7496.	7.0	63
52	Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer. Clinical Cancer Research, 2004, 10, 8351-8356.	7.0	60
53	The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer. Urology, 2014, 83, 369-375.	1.0	60
54	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	2.5	58

#	ARTICLE	IF	CITATIONS
55	Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 401-406.	7.1	56
56	An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1529-1538.	6.4	55
57	Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene. Molecular Endocrinology, 2002, 16, 2323-2337.	3.7	54
58	A Novel Dual-targeted Lentiviral Vector Leads to Specific Transduction of Prostate Cancer Bone Metastases In Vivo After Systemic Administration. Molecular Therapy, 2007, 15, 1973-1981.	8.2	54
59	Trefoil factor 3 is overexpressed in human prostate cancer. Prostate, 2004, 61, 209-214.	2.3	53
60	Preoperative p27 Status is an Independent Predictor of Prostate Specific Antigen Failure Following Radical Prostatectomy. Journal of Urology, 2003, 169, 1325-1330.	0.4	51
61	Quantitative ImmunoPET of Prostate Cancer Xenografts with ⁸⁹ Zr- and ¹²⁴ I-Labeled Anti-PSCA A11 Minibody. Journal of Nuclear Medicine, 2014, 55, 452-459.	5.0	51
62	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Molecular Therapy, 2021, 29, 2335-2349.	8.2	51
63	Stem cell genes in androgen-independent prostate cancer. , 1998, 17, 391-399.		50
64	MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. Journal of Magnetic Resonance Imaging, 2012, 36, 697-703.	3.4	50
65	Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. European Urology, 2019, 76, 18-23.	1.9	50
66	Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 2237-2243.	7.0	49
67	Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 177-182.	5.0	49
68	Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. Journal of Urology, 2018, 199, 453-458.	0.4	47
69	Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. , 1999, 40, 269-273.		45
70	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6457-E6466.	7.1	44
71	Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clinical Cancer Research, 2016, 22, 1403-1412.	7.0	40
72	Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. Journal of Nuclear Medicine, 2018, 59, 1398-1405.	5.0	40

#	ARTICLE	IF	CITATIONS
73	Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. <i>Protein Engineering, Design and Selection</i> , 2008, 22, 209-216.	2.1	38
74	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	1.9	37
75	Radical prostatectomy: value of prostate MRI in surgical planning. <i>Abdominal Imaging</i> , 2012, 37, 664-674.	2.0	36
76	High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1505-1515.	7.0	36
77	Prostate Microstructure in Prostate Cancer Using 3-T MRI with Diffusion-Relaxation Correlation Spectrum Imaging: Validation with Whole-Mount Digital Histopathology. <i>Radiology</i> , 2020, 296, 348-355.	7.3	35
78	Deletion of PSCA increases metastasis of TRAMP α -induced prostate tumors without altering primary tumor formation. <i>Prostate</i> , 2008, 68, 139-151.	2.3	34
79	Diffusion Tensor Magnetic Resonance Tractography of the Prostate: Feasibility for Mapping Periprostatic Fibers. <i>Urology</i> , 2012, 80, 219-223.	1.0	34
80	Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 952-957.	1.6	33
81	Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. <i>Theranostics</i> , 2018, 8, 5903-5914.	10.0	33
82	The Evolving Role of Prostate-Specific Membrane Antigen α -Based Diagnostics and Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 321-330.	3.8	33
83	Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. <i>Prostate</i> , 2013, 73, 1378-1390.	2.3	31
84	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	6.4	30
85	Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. <i>Journal of Urology</i> , 2021, 205, 444-451.	0.4	30
86	Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6367-6378.	7.0	29
87	Prostate diffusion imaging with distortion correction. <i>Magnetic Resonance Imaging</i> , 2015, 33, 1178-1181.	1.8	29
88	Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. <i>Radiology</i> , 2017, 284, 109-119.	7.3	29
89	Target antigens for prostate cancer immunotherapy. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 437-449.	5.9	28
90	Multidimensional MR spectroscopic imaging of prostate cancer <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2014, 27, 53-66.	2.8	28

#	ARTICLE	IF	CITATIONS
91	A 17-Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. <i>Journal of Urology</i> , 2018, 200, 564-572.	0.4	28
92	Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI. <i>American Journal of Roentgenology</i> , 2019, 213, W134-W142.	2.2	28
93	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	7.1	27
94	Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 4-11.	1.6	24
95	Role of prostate stem cell antigen in prostate cancer research. <i>Current Opinion in Urology</i> , 2002, 12, 401-406.	1.8	23
96	Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. <i>Prostate</i> , 2003, 55, 9-19.	2.3	23
97	Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. <i>Clinical Cancer Research</i> , 2019, 25, 188-200.	7.0	23
98	A fully human scFv phage display library for rapid antibody fragment reformatting. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 307-316.	2.1	22
99	A system using patient-specific 3D-printed molds to spatially align in vivo MRI with ex vivo MRI and whole-mount histopathology for prostate cancer research. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 270-279.	3.4	22
100	Improvements in prostate brachytherapy dosimetry due to seed stranding. <i>Brachytherapy</i> , 2007, 6, 44-48.	0.5	21
101	Detection Threshold and Reproducibility of ^{68}Ga -PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397.	5.0	21
102	Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. <i>Cancer</i> , 2019, 125, 2955-2964.	4.1	21
103	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.	7.1	21
104	Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS [®] version 2 Category and Staging with Whole Mount Histopathology Correlation. <i>Journal of Urology</i> , 2019, 201, 496-502.	0.4	21
105	Molecular Markers and Prostate Cancer Prognosis. <i>Clinical Prostate Cancer</i> , 2004, 3, 157-164.	2.1	20
106	MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. <i>Frontiers in Oncology</i> , 2015, 5, 30.	2.8	20
107	The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 258-266.	3.1	19
108	Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 595-603.	0.4	19

#	ARTICLE	IF	CITATIONS
109	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. <i>European Urology</i> , 2022, 82, 106-114.	1.9	19
110	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	1.9	18
111	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	1.9	18
112	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. <i>European Urology Oncology</i> , 2022, 5, 100-103.	5.4	18
113	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	7.1	18
114	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€“Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	5.9	18
115	Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. <i>Urology</i> , 2003, 61, 1187-1192.	1.0	17
116	Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. <i>Journal of Urology</i> , 2018, 199, 1218-1223.	0.4	17
117	Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. <i>BMC Cancer</i> , 2019, 19, 291.	2.6	17
118	Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2. <i>Abdominal Radiology</i> , 2020, 45, 2225-2234.	2.1	17
119	Efficacy of a preprostatectomy multi-modal penile rehabilitation regimen on recovery of postoperative erectile function. <i>International Journal of Impotence Research</i> , 2020, 32, 323-328.	1.8	17
120	Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2. <i>American Journal of Roentgenology</i> , 2020, 214, 1101-1111.	2.2	17
121	Multi-parametric magnetic resonance imaging as a management decision tool. <i>Translational Andrology and Urology</i> , 2017, 6, 472-482.	1.4	16
122	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 544-552.	5.4	16
123	PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. <i>Journal of Urology</i> , 2019, 201, 91-97.	0.4	16
124	Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage. <i>BJU International</i> , 2019, 124, 275-281.	2.5	14
125	The Role of Opioids and Their Receptors in Urological Malignancy: A Review. <i>Journal of Urology</i> , 2020, 204, 1150-1159.	0.4	14
126	Accelerated echo planar J â€“resolved spectroscopic imaging in prostate cancer: a pilot validation of nonâ€“linear reconstruction using total variation and maximum entropy. <i>NMR in Biomedicine</i> , 2015, 28, 1366-1373.	2.8	13

#	ARTICLE	IF	CITATIONS
127	3T multiparametric MR imaging, PIRADSV2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard. <i>Abdominal Radiology</i> , 2018, 43, 3117-3124.	2.1	13
128	Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification. <i>Diagnostics</i> , 2021, 11, 1785.	2.6	13
129	Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. <i>Biochemical Pharmacology</i> , 2006, 72, 1257-1267.	4.4	12
130	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 930-935.	0.8	12
131	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	5.9	12
132	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	1.9	12
133	Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. <i>Journal of Urology</i> , 2002, 168, 2615-2623.	0.4	11
134	Fine-tuning robot-assisted radical prostatectomy planning with MRI. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 766-775.	1.6	11
135	Risk stratification of prostate cancer in the modern era. <i>Current Opinion in Urology</i> , 2015, 25, 246-251.	1.8	11
136	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.8	11
137	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 135-139.	3.9	11
138	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.8	10
139	Evaluation of [¹³¹ I]- and [¹⁷⁷ Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2020, 22, 1380-1391.	2.6	10
140	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.	7.0	10
141	Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation. <i>American Journal of Roentgenology</i> , 2019, 212, W122-W131.	2.2	8
142	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e53-e55.	1.9	8
143	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	8
144	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 207-209.	3.9	8

#	ARTICLE	IF	CITATIONS
145	Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Triecta Outcomes: A Randomized Clinical Trial. <i>Journal of Urology</i> , 2022, 208, 618-625.	0.4	8
146	Risk stratification of prostate cancer 2016. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S54-S59.	1.2	6
147	[89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. <i>Molecular Imaging and Biology</i> , 2020, 22, 367-376.	2.6	6
148	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	3.9	6
149	The utility of prostate MRI within active surveillance: description of the evidence. <i>World Journal of Urology</i> , 2022, 40, 71-77.	2.2	6
150	Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena. <i>Journal of Hematology and Oncology</i> , 2022, 15, 48.	17.0	6
151	Genetic alterations in prostate cancer. <i>Current Urology Reports</i> , 2004, 5, 157-165.	2.2	5
152	Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e353-e356.	1.3	5
153	First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. <i>European Urology Oncology</i> , 2018, 1, 378-385.	5.4	4
154	Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 401.e19-401.e25.	1.6	4
155	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2017, 107, 171-177.	1.0	3
156	Wrong to be Right. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1-5.	1.3	3
157	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	5.4	3
158	Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. <i>Abdominal Radiology</i> , 2018, 43, 2487-2496.	2.1	2
159	Anatomic and Molecular Imaging in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030619.	6.2	2
160	Focal Therapy Should Not Be Considered for Men with Gleason Grade Group 3-5 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 203-204.	3.1	2
161	MRI-guided Biopsy in Active Surveillance of Prostate Cancer. <i>Journal of Urology</i> , 2021, , 101097JU00000000000002343.	0.4	2
162	Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1497-1499.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI. <i>Prostate</i> , 2021, 81, 521-529.	2.3	1
164	Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. <i>Anticancer Research</i> , 2017, 37, 1237-1242.	1.1	1
165	Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. <i>Canadian Journal of Urology</i> , 2020, 27, 10352-10362.	0.0	1
166	Genetic alterations in prostate cancer. <i>Current Prostate Reports</i> , 2004, 2, 51-59.	0.1	0
167	What are the operating characteristics of PSA screening for prostate cancer?. <i>Nature Reviews Urology</i> , 2006, 3, 74-75.	1.4	0
168	What factors affect the PSA relapse-free survival times in patients treated with permanent seed brachytherapy?. <i>Nature Reviews Urology</i> , 2007, 4, 650-651.	1.4	0
169	Is Targeted Biopsy Applicable to Patients on Active Surveillance?. <i>European Urology</i> , 2017, 71, 181-182.	1.9	0
170	Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial. <i>European Urology</i> , 2019, 75, 591-592.	1.9	0
171	Caught Between a Rock and a Hard Place. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 846-847.	0.8	0
172	860: Prostate Stem Cell Antigen (PSCA) Expression is Associated with Gleason Score, Seminal Vesicle Invasion, and Capsular Invasion in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 227-228.	0.4	0